In:
Clinical Nuclear Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 46, No. 8 ( 2021-8), p. 627-634
Kurzfassung:
We aimed to evaluate the role of 18 F-FDG PET/CT in predicting patient outcome following chimeric antigen receptor T (CAR T) cells infusion in aggressive B-cell lymphoma. Methods 18 F-FDG PET/CT data before leukapheresis, before CAR T-cell infusion and 1 month (M1) after CAR T-cell infusion, from 72 patients were retrospectively analyzed. SUVmax, total lesion glycolysis (TLG), metabolic tumor volume (MTV), and parameters describing tumor kinetics were calculated for each 18 F-FDG PET/CT performed. The aim was to evaluate the prognostic value of 18 F-FDG PET/CT metabolic parameters for predicting progression-free survival (PFS) and overall survival (OS) following CAR T-cell therapy. Results Regarding PFS, ∆MTV pre-CAR and ∆TLG pre-CAR were found to be more discriminating compared with metabolic parameters at preinfusion. Median PFS in patients with a ∆MTV pre-CAR of less than 300% was 6.8 months (95% confidence interval [CI], 2.8 months to not reached) compared with 2.8 months (95% CI, 0.9–3.0 months) for those with a value of 300% or greater ( P = 0.004). Likewise, median PFS in patients with ∆TLG pre-CAR of less than 420% was 6.8 months (95% CI, 2.8 months to not reached) compared with 2.7 months (95% CI, 1.3–3.0 months) for those with a value of 420% or greater ( P = 0.0148). Regarding OS, metabolic parameters at M1 were strongly associated with subsequent outcome. SUVmax at M1 with a cutoff value of 14 was the most predictive parameter in multivariate analysis, outweighing other clinicobiological variables ( P 〈 0.0001). Conclusions Disease metabolic volume kinetics before infusion of CAR T cells seems to be superior to initial tumor bulk itself for predicting PFS. For OS, SUVmax at M1 might adequately segregate patients with different prognosis.
Materialart:
Online-Ressource
ISSN:
1536-0229
,
0363-9762
DOI:
10.1097/RLU.0000000000003756
Sprache:
Englisch
Verlag:
Ovid Technologies (Wolters Kluwer Health)
Publikationsdatum:
2021
ZDB Id:
2045053-9
